Management of Chronic Hepatitis B: New Stopping Rules


  • Malak Noureddine Rafik Hariri University Hospital
  • Iyad Issa Rafik Hariri University Hospital
  • Rami Moucari Advanced Cure Diagnostic Center



Chronic hepatitis B virus, management, interferon, entecavir, tenofovir, lamivudine, adefovir


Chronic hepatitis B (CHB) treatment is limited by the availability of antiviral agents and the variable response to those agents. Currently, the only approved antiviral agents are Pegylated interferon and nucleos(t)ide analogues. The response to these therapies varies widely between CHB patients. Thus, the patients with non favorable response are ultimately exposed to unnecessary side effects and costs. All current guidelines provide information regarding the time to initiate therapy. However, a clear consensus regarding the predictors of non response and consequently terminating the treatment is still lacking. Many studies that determine the adequacy of the use of predictive markers early in the course of the disease will be reviewed here. During Pegylated interferon therapy, combination of decline in serum HBV DNA and HbsAg levels from baseline at week 12 could generate a solid stopping rule. Using nucleos(t)ide analogues in chronic HbeAg positive patients, the on-treatment HbsAg quantitation at 6 months appears to have a useful role in determining the duration of therapy in patients who achieve HbeAg loss (or seroconversion) during treatment. In chronic HbeAg negative patients, the Asia pacific association for the study of liver (APASL) stopping rules are adequate with proper off-therapy monitoring. Furthermore, the durability of off-therapy response for both classes based on long term follow up studies will be discussed here. Through this review we will present a clear generation of stopping rules to guide the antiviral therapy early enough to predict non-response and shift to other agents. Therefore, adopting a cost effective approach in the treatment of chronic hepatitis B.


Author Biography

Iyad Issa, Rafik Hariri University Hospital

Department of Gastroenterology & Hepatology

Head of Division


Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745 [PMID: 9392700 DOI: 10.1056/ NEJM199712113372406]

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]

Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]

Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 2007; 11: 685-706 [PMID: 17981225 DOI: 10.1016/j.cld.2007.08.002]

Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010; 15 Suppl 3: 3-14 [PMID: 21041899 DOI: 10.3851/IMP1619]

Doo EC, Ghany MG. Hepatitis B viriology for clinicians. Clin Liver Dis 2010; 14: 397-408 [PMID: 20638021 DOI: 10.1016/j.cld.2010.05.001]

Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92 [PMID: 19217993 DOI: 10.1016/SO140-6736(09)60207-5]

Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7 [PMID: 12029639 DOI: 10.1053/jhep.2002.33638]

Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34 [PMID: 15178498 DOI: 10.1016/j.amjmed.2003.12.040]

Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-31 [PMID: 2010157 DOI: 10.1002/hep.1840130403]

G Fattovich, N Olivari, M Pasino, M D’Onofrio, E Martone, F Donato. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. GUT 2008; 57: 84-90 [PMID: 17715267 DOI: 10.1136/gut.2007.128496]

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

Brunetto MR, Oliviri F, Colombatto P, Moriconi F, Ciccorossi p, et al. Hepatitis B surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology 2010; 139: 483-490 [PMID: 20451520 DOI: 10.1053/j.gastro.2010.04.052]

Martinot-Peignoux, Lapalus M, Laouenan C, Lada O, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. Journal of Clinical Virology 2013; 58: 401-407 [PMID:24004660 DOI: 10.1016/j.jcv.2013.08.010]

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, et al. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med 2004; 351: 1206-1217 [PMID: 15371578 DOI: 10.1056/NEJMoa040431]

Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. Gastroenterology 2009; 136: 2169-2179 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, et al. Hepatitis B surface antigen levels: association with 5-year response to peg interferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013; 7: 88-97 [PMID: 23518903 DOI: 10.1007/s12072-012-9343-x]

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peg interferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150 [PMID: 19338056 DOI: 10.1002/hep.22760]

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, et al. Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients. Hepatology 2009; 49: 1151-1157 [PMID: 19115222 DOI:10.1002/hep.22744]

Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461 [PMID: 20683945 DOI: 10.1002/hep.23722]

Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011 [PMID: 22245886 DOI: 10.1016/j.jhep.2011.12.007]

Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis B. Hepatology 1986; 6: 167-72 [PMID: 3957228 DOI:10.1002/1840060203]

Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med 1996; 334: 1422-7 [PMID: 8618580 DOI: 10.1056/NEJM199605303342202]

Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. N Engl J Med 2005; 352: 2682-95 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]

Liaw YF, Jia JD, Chan HLY, Han KH, Tanwandee T, et al. Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C. Hepatology 2011; 54: 1591-1599 [PMID: 22045673 DOI:10.1002/hep.24555]

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, et al. Sustained HBeAg and HBsAg Loss After Long Term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b. Gastroenterology 2008; 135: 459-467 [PMID: 18585385 DOI: 10.1053/j.gastro.2008.05.031]

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, et al. Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B surface Antigen Levels. Hepatology 2013; 58: 872-880 [PMID: 23553752 DOI:10.1002/hep.26436]

Heijtink RA, Kruining J, Honkoop P, Kuhns MC, Hop WC, et al. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J. Med. Virol. 1997; 53: 282-287 [PMID: 9365897 DOI: 10.1002/(SICI)1096-9071(199711)53:3<282::aid-jmv18>3.0.CO;2-J]

Tangkijvanich P, Komolmit P, Mahachai V, Sanguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pregylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatology Research 2010; 40: 269-277 [PMID: 20070399 DOI: 10.1111/ j.1872-034X.2009.00592.x]

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10): 1001-10 [PMID: 16525137 DOI:10.1056/NEJMoa051285]

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354(10): 1011-20 [PMID: 16525138 DOI: 10.1056/NEJMoa051287]

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348(9): 808-16 [PMID: 12606735 DOI:10.1056/NEJMoa020681]

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348(9): 800-7 [PMID: 12606734 DOI:10.1056/NEJMoa021812]

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357(25): 2576-88 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]

Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trail results: telbivudine Is superior to lamivudine in patient with chronic hepatitis B. Gastroenterology 2009; 136(2): 486-95 [PMID: 19027013 DOI:10.1053/j.gastro.2008.10.026]

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55 [PMID: 19052126 DOI:10.1056/NEJMoa0802878]

Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroeneterology 2011; 140: 132-143 [PMID: 20955704 DOI:10.1053/j.gastro.2010.10.011)

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75 [PMID: 23234725 DOI:10.1016/S0140-6736(12)61425-1]

Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Eng J Med 2006; 354: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285]

Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444 [PMID: 17983800 DOI:10.1053/j.gastro.2007.08.025]

Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430 [PMID: 20049753 DOI:10.1002/hep.23327]

Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]

Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184 [PMID: 16024289 DOI: 10.1016/j.hepres.2005.02.006]

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long term Entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]

Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterolgy 2010; 139: 491-498 [PMID: 20381492 DOI:10.1053/j.gastro.2010.03.059]

Kim SS, Lee D, Lee MH, Cheong JY, Cho SW. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatology Research 2013; 43 :219-227 [PMID: 22835015 DOI:10.1111/j.1872-034X.2012.01065.x]

Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-636 [PMID: 22659218 DOI:10.1053/j.gastro.2012.05.039]

Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561 [DOI: 10.1007/s12072-012-9365-4]

Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-1896 [PMID: 23744454 DOI: 10.1002/hep.26549]